Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553941 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
A Phase 1 study of Chronic Myelomonocytic Leukemia and Previously Treated Myelodysplastic Syndrome, sponsored by Brian Jonas.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT02553941: Completed Phase 1 study of Chronic Myelomonocytic Leukemia and Previously Treated Myelodysplastic Syndrome, sponsored by Brian Jonas.
NCT02553941 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Previously Treated Myelodysplastic Syndrome that has completed, run by Brian Jonas. The registered enrollment target is 21 participants, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02553941, a Phase 1 study of Chronic Myelomonocytic Leukemia and Previously Treated Myelodysplastic Syndrome, has completed, sponsored by Brian Jonas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrutinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
For each adverse event, the percentage of subjects who experience at least 1 occurrence of the given event will be summarized.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Ibrutinib
Study Locations (5)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California San Diego - San Diego
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-05-17 |
| Est. Completion | 2019-11-07 |
| Phase | Phase 1 |
What the finished NCT02553941 record still lists
NCT02553941 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (76% lower).
The record links to 5 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT02553941 lists 5 locations in 1 state (California).
Frequently Asked Questions
What is clinical trial NCT02553941 about?
NCT02553941 is a clinical study titled "Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome". This phase Ib trial studies the side effects and best dose of ibrutinib when given together with azacitidine in treating patients with myelodysplastic syndrome that is likely to occur or spread (higher risk) and who were previously treated or untreated and unfit for or refused intense therapy. Ibrut...
What is the current status of trial NCT02553941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2016-05-17. Estimated completion is 2019-11-07.
What conditions does trial NCT02553941 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, de Novo Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation.
What interventions are being tested in trial NCT02553941?
The interventions under investigation include: Azacitidine (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02553941?
This trial is sponsored by Brian Jonas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02553941 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02553941's enrollment target sits among peer trials
21 67th of 73 higher than 7 of 73 other Chronic Myelomonocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelomonocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI